Where Biopharma Quality Meets Innovation: Hzymes at QbD 2026

Hzymes Biotech to Exhibit at QbD 2026 in Beijing

Hzymes Biotech is pleased to announce its participation in the 7th Quality by Design (QbD) Biopharmaceutical Quality Science Conference, which will be held on July 10–11, 2026, at the Beijing U-Town Crown Plaza Hotel.

Centered on the theme “Building a Strong Quality Foundation to Drive the Future of the Industry”, QbD 2026 will bring together leading experts, industry executives, researchers, and regulatory representatives from across the global biopharmaceutical sector. The conference will cover key topics including monoclonal antibodies, ADCs, peptides, cell and gene therapy (CGT), oligonucleotide therapeutics, AI-driven drug development, and global regulatory strategies.

The event will feature four parallel sessions and ten thematic tracks, focusing on critical areas such as quality control, process characterization, analytical method validation, and regulatory compliance. Attendees will include professionals from quality assurance, quality control, R&D, formulation, regulatory affairs, manufacturing, project management, and executive leadership, offering a comprehensive platform for knowledge exchange and collaboration.

Visit Hzymes Biotech at Booth A07

At QbD 2026, Hzymes Biotech will showcase its latest innovations at Booth A07. The company will present integrated solutions across cell and gene therapy, protein and antibody (including conjugated antibodies), peptide and nucleic acid therapeutics, as well as customized technical services.

Visitors are warmly invited to connect with our team and explore how Hzymes Biotech supports advanced biopharmaceutical development with high-quality enzymes, reagents, and process solutions.